Company Overview
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical entity focused on the development and commercialization of therapeutics and pharmaceutical products across the People's Republic of China, the United States, and international markets. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a focus on research-intensive activities aimed at creating innovative medical treatments. According to available data, the organization employs 233 individuals and maintains a market capitalization of $11.85M. The company generated $26.85M in annual revenue during the trailing twelve-month period. These figures indicate that CASI is a small-cap biotechnology firm with a relatively modest revenue base, reflecting the typical financial profile of companies in early to mid-stage development that are still navigating the high-cost environment of drug discovery and commercialization.
Financial Health
The company reported $26.85M in revenue for the trailing twelve months, while simultaneously recording a net income loss of $-49,385,000 and an EBITDA of $-42,272,500. The substantial gap between the positive revenue of $26.85M and the significant negative net income reveals a cost structure where operating expenses, likely driven by research and development activities, far exceed total sales. Regarding cash flow, the company reports N/A for free cash flow, suggesting that the firm may be in a cash-burning phase where capital expenditures or operating outflows exceed cash generation, limiting immediate financial flexibility. The gross margin stands at 35.8%, indicating that the company retains a moderate portion of revenue after direct production costs. However, the operating margin is severely negative at -333.1%, and the profit margin is -184.0%, both of which highlight intense operational inefficiencies or high overhead costs relative to current sales levels. On the balance sheet, the company holds $4.68M in cash against $18.86M in debt, resulting in a debt-to-equity ratio of N/A. This disparity indicates a leveraged balance sheet where debt obligations significantly outweigh liquid assets. Additionally, the current ratio is 0.30, which indicates that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity challenges. Finally, the return on equity is N/A due to the negative equity position, and the return on assets is -61.8%, revealing that management is currently generating negative returns on the assets deployed to run the business.
Valuation Assessment
Valuation multiples for CASI show a trailing P/E ratio of N/A and a forward P/E of -0.36, implying that the market is pricing the stock based on future expectations rather than current profitability, though the negative forward P/E suggests anticipated losses or a specific accounting adjustment. The price-to-book ratio is -0.55, which indicates that the market values the company at a significant discount relative to its book value, a common characteristic for biotechnology firms with intangible assets that are not fully captured on traditional balance sheets. Alternative valuation metrics include a price-to-sales ratio of 0.44 and an EV/EBITDA of -0.71, suggesting that investors are willing to pay less than half a dollar for every dollar of sales, reflecting high perceived risk. The stock has traded between a 52-week high of $3.09 and a 52-week low of $0.74. Without a specific current price provided in the facts, the valuation context relies on these bounds, showing a wide trading range that reflects high volatility. The beta is 0.89, which means the stock's price volatility is slightly lower than the broader market, indicating it does not fluctuate as aggressively as the overall index during market movements.
Growth & Income
Revenue growth year-over-year is -60.5%, while earnings growth year-over-year is N/A, indicating that the company is currently experiencing a contraction in its top line and lacks sufficient earnings to measure growth rates effectively. Since the company does not pay dividends, there is no dividend yield or payout ratio to analyze for sustainability. As a non-dividend payer, the company reinvests any available earnings or capital into growth initiatives, such as research and development, rather than distributing income to shareholders. The overall growth and income profile for CASI is characterized by significant revenue contraction and a complete absence of dividend income, which is typical for biotechnology companies that prioritize capital allocation toward product development over shareholder returns during periods of negative earnings.